TrialSignal
Clinical trial intelligence report
Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02080169-Jul 28, 2026
NCT ID
NCT02080169
Status
UNKNOWN
Phase
PHASE4
Sponsor
Qilu Hospital of Shandong University
Executive brief
Investment-Ready Snapshot
Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients is a PHASE4 clinical asset sponsored by Qilu Hospital of Shandong University in Delirium. SEO and diligence focus: midazolam, Dexmedetomidine, Fentanyl, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02080169
Indication
Delirium
Modality
small molecule
Target
midazolam, Dexmedetomidine, Fentanyl
Intervention
midazolam, Dexmedetomidine, Fentanyl
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.